Buxó, E. (Elvira)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
2 results
Search Results
Now showing 1 - 2 of 2
- Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab(2017) Jiménez-Fonseca, P. (Paula); López, C. (Carolina); Azkarate, A. (Aitor); Custodio, A. (Ana); Mangas, M. (Monserrat); Viudez, A. (Antonio); Echavarría, I. (Isabel); Sanchez-Bayona, R. (Rodrigo); Buxó, E. (Elvira); Hernández, R. (Raquel); Longo, F.; Pericay, C. (Carles); Carmona-Bayonas, A. (Alberto); Ramchandani, A. (Avinash); Lacalle, A. (Alejandra); Fernández-Montes, A. (Ana); Macías-Declara, I. (Ismael); García-García, T. (Teresa); Sánchez-Lorenzo, M. L. (María Luisa); Cano, J. M. (Juana María); Rodríguez-Palomo, A. (Alberto); Álvarez-Manceñido, F. (Felipe); Visa, L. (Laura); Limón, M. L. (María-Luisa)Background: To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. Methods: Nine hundred twenty-four AOA patients treated at 28 Spanish teaching hospitals from January 2008 to September 2014 were used as derivation cohort. The result of an adjusted-Cox proportional hazards regression was represented as a nomogram and web-based calculator. The model was validated in 502 prospectively recruited patients treated between October 2014 and December 2016. Harrell's c-index was used to evaluate discrimination. Results: The nomogram includes seven predictors associated with OS: HER2-positive tumours treated with trastuzumab, Eastern Cooperative Oncology Group performance status, number of metastatic sites, bone metastases, ascites, histological grade, and neutrophil-to-lymphocyte ratio. Median OS was 5.8 (95% confidence interval (CI), 4.5–6.6), 9.4 (95% CI, 8.5–10.6), and 14 months (95% CI, 11.8–16) for high-, intermediate-, and low-risk groups, respectively (P<0.001), in the derivation set and 4.6 (95% CI, 3.3–8.1), 12.7 (95% CI, 11.3–14.3), and 18.3 months (95% CI, 14.6–24.2) for high-, intermediate-, and low-risk groups, respectively (P<0.001), in the validation set. The nomogram is well-calibrated and reveals acceptable discriminatory capacity, with optimism-corrected c-indices of 0.618 (95% CI, 0.591–0.631) and 0.673 (95% CI, 0.636–0.709) in derivation and validation groups, respectively. The AGAMENON nomogram outperformed the Royal Marsden Hospital (c-index=0.583; P=0.00046) and Japan Clinical Oncology Group prognostic indices (c-index=0.611; P=0.03351). Conclusions: We developed and validated a straightforward model to predict survival in Caucasian AOA patients initiating first-line polychemotherapy. This model can contribute to inform clinical decision-making and optimise clinical trial design.
- Publicación: Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer(2016) Jiménez-Fonseca, P. (Paula); Álvarez-Llosa, R. (Renata); Serrano, R. (Raquel); Custodio, A. (Ana); Mangas, M. (Monserrat); Viudez, A. (Antonio); Alsina, M. (María); Garrido, M. (Marcelo); Echavarría, I. (Isabel); Hurtado-Nuño, A. (Alicia); Sanchez-Bayona, R. (Rodrigo); Buxó, E. (Elvira); Hernández, R. (Raquel); Carmona-Bayonas, A. (Alberto); Ramchandani, A. (Avinash); Castañon-Alvarez, E. (Eduardo); Macías-Declara, I. (Ismael); Pimentel, P. (Paola); García-García, T. (Teresa); Sánchez-Lorenzo, M. L. (María Luisa); Cano, J. M. (Juana María); Rodríguez-Palomo, A. (Alberto); Felices-Lobera, M. P. (María Pilar); Visa, L. (Laura); Gallego-Plazas, J. (Javier); Cerdá, P. (Paula); Gómez-Martin, C. (Carlos); Limón, M. L. (María-Luisa)Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.